Skip to content
Back to News Hub
Insurance, Medical Health Aged Care

GMHBA celebrates fourth consecutive Canstar Award win with national recognition for Outstanding Value

GMHBA Limited < 1 min read

Great news,

We’re excited to share a new achievement with you:

GMHBA celebrates fourth consecutive Canstar Award win with national recognition for Outstanding Value

Not-for-profit health fund GMHBA has once again been recognised by leading consumer comparison site Canstar, taking home six awards for providing outstanding value health insurance in 2025. 

Read more

 


Contact details:

GMHBA Head of Corporate Communications Meg Rayner

0458 418 823 or [email protected]

For the latest announcements and updates visit GMHBA Media Centre.

More from this category

  • CharitiesAidWelfare, Medical Health Aged Care
  • 31/08/2026
  • 06:00
Leukaemia Foundation

Cost of cancer crisis: 1 in 8 blood cancer patients missing, delaying or cancelling treatment because they can’t afford it

Interview Opportunities Leukaemia Foundation CEO Chris Tanti / Leukaemia Foundation Head of Research BillStavreski:Our spokespersons can talk on the points raised in the media…

  • Contains:
  • CharitiesAidWelfare, Medical Health Aged Care
  • 31/08/2026
  • 06:00
Leukaemia Foundation

Cost of cancer crisis: 1 in 8 blood cancer patients missing, delaying or cancelling treatment because they can’t afford it

Interview Opportunities Leukaemia Foundation CEO Chris Tanti / Leukaemia Foundation Head of Research BillStavreski:Our spokespersons can talk on the points raised in the media…

  • Contains:
  • Government Federal, Medical Health Aged Care
  • 30/08/2026
  • 07:00
Ethical Strategies on behalf of MSD Australia & New Zealand

Government funds medicine for approximately 10,000 eligible Australians with certain advanced or metastatic cancers

Cancer patients, advocates, and doctors are joining MSD in welcoming a milestone decision by the Federal Government to provide subsidised access to KEYTRUDA® (pembrolizumab) for over 10,000 newly eligible Australians over the next four years, with certain advanced and metastatic cancers.1 From 1 September 2026, the cost of KEYTRUDA will be subsidised through the Pharmaceutical Benefits Scheme (PBS) for eligible Australians whose cancer cannot be surgically removed and is known to be sensitive to immunotherapy.1 This means eligible patients, including those with rare or less common cancers with limited treatment options, will pay just $7.70 (concession) or $25.00 (general patients)…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.

Book a demo Explore our plans